News•Mar 25, 2026
An Indication Selection Resource for Longevity Companies
Norn Group has released a free, detailed spreadsheet that maps 47 age‑related disease indications, providing mechanisms, incidence, market size, clinical endpoints, animal models, and trial cost estimates. The guide is designed to help longevity‑focused startups choose FDA‑approved disease targets rather than a vague “aging” label, a strategy required to attract billion‑dollar funding streams. By outlining pre‑clinical model relevance, trial duration, and unmet‑need metrics, the resource aims to de‑risk investment decisions and accelerate path‑to‑market. The authors stress that without a clear disease indication, most longevity companies struggle to raise capital and achieve regulatory approval.
